This collaboration equips practices and manufacturers with integrated real-world clinical evidence and contracting intelligence to support the sustainability ofThis collaboration equips practices and manufacturers with integrated real-world clinical evidence and contracting intelligence to support the sustainability of

AllyGPO and MiBA Launch Strategic Partnership to Bring Unprecedented Data-Driven Insights to Community Oncology

2026/01/08 22:16
3분 읽기
이 콘텐츠에 대한 의견이나 우려 사항이 있으시면 crypto.news@mexc.com으로 연락주시기 바랍니다

This collaboration equips practices and manufacturers with integrated real-world clinical evidence and contracting intelligence to support the sustainability of independent practices.  

FRISCO, Texas and TAMPA, Fla., Jan. 8, 2026 /PRNewswire/ — AllyGPO®, a technology-forward oncology drug group purchasing organization, and MiBA (Meaningful Insights Biotech Analytics), a leader in AI-powered oncology analytics, today announced a groundbreaking strategic partnership to transform how community oncology practices access and apply real-world data. The partnership leverages MiBA’s advanced clinical data insights and precision analytics and AllyGPO’s practice intelligence center, AllyIQ®, to close long-standing information gaps in oncology care and drive improved outcomes for patients and community practices.

Together, the organizations address the industry’s critical need to accelerate the adoption of data-driven decision-making in community oncology. The alliance introduces a scalable model for therapy optimization. Additionally, connecting MiBA’s validated data engine and AllyGPO’s contracting expertise enables the execution of appropriate-use GPO agreements that deliver measurable value across community oncology and pharmaceutical partners. A robust pipeline of partners and therapies is slated for activation in 2026.

“MiBA was founded to transform oncology through insights that truly serve the community,” said Jason Baroff, Managing Partner of MiBA. “Partnering with AllyGPO amplifies that mission. Together, we’re delivering insights that not only enhance patient care but also inspire practices to rethink what’s possible. We’re humbled by the response from our partners and excited to drive this change together.”

“This partnership allows community oncology to break free from legacy business frameworks,” added Mark Moch, Managing Partner of MiBA. “By pairing our high-accuracy, AI-powered clinical analytics with AllyGPO’s comprehensive platform for managing oncology drugs and contract performance, we’re empowering practices to thrive in a new era of data-driven care. We’re rallying a call for the industry to join us in this transformation.”

“At AllyGPO, our goal is to earn our members’ business every day by providing transparency, innovation, and value,” shared Brian Ansay, CEO of AllyGPO. “Working with MiBA advances this mission and helps us support a growing network of independent community oncology practices aligned in purpose, enabled by technology, and dedicated to delivering the highest-quality patient care.”

“The synergy between AllyGPO’s contracting expertise, AllyIQ’s analytics, and MiBA’s innovative clinical tools is game changing for community oncology,” said Aaron Denning, Chief Commercial Officer of AllyGPO. “Together, we’re delivering timely insights that improve patient outcomes and empower practices to lead the next generation of community oncology care.”

About MiBA
MiBA (Meaningful Insights Biotech Analytics) is a Tampa-based innovator in AI-powered oncology analytics, delivering real-world evidence and tools that optimize therapy matching and patient outcomes. Focused on community oncology, MiBA’s platforms transform complex data into actionable, high-accuracy insights that drive innovation and efficiency. For more information, visit mibanalytics.com.

About AllyGPO
AllyGPO is a tech-forward group purchasing organization empowering community oncology practices to operate more efficiently, improve financial performance, and stay independent. AllyIQ®, AllyGPO’s advanced platform for comprehensive drug management, brings together intelligent inventory management with AI-supported analytics designed to deliver more accurate, timely, and actionable insights. Learn more at www.AllyGPO.com.

Media Contact:
Dara Shulman
866-255-9476
407162@email4pr.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/allygpo-and-miba-launch-strategic-partnership-to-bring-unprecedented-data-driven-insights-to-community-oncology-302655984.html

SOURCE AllyGPO and MiBA Analytics

시장 기회
RealLink 로고
RealLink 가격(REAL)
$0.06456
$0.06456$0.06456
-0.17%
USD
RealLink (REAL) 실시간 가격 차트
면책 조항: 본 사이트에 재게시된 글들은 공개 플랫폼에서 가져온 것으로 정보 제공 목적으로만 제공됩니다. 이는 반드시 MEXC의 견해를 반영하는 것은 아닙니다. 모든 권리는 원저자에게 있습니다. 제3자의 권리를 침해하는 콘텐츠가 있다고 판단될 경우, crypto.news@mexc.com으로 연락하여 삭제 요청을 해주시기 바랍니다. MEXC는 콘텐츠의 정확성, 완전성 또는 시의적절성에 대해 어떠한 보증도 하지 않으며, 제공된 정보에 기반하여 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다. 본 콘텐츠는 금융, 법률 또는 기타 전문적인 조언을 구성하지 않으며, MEXC의 추천이나 보증으로 간주되어서는 안 됩니다.

USD1 Genesis: 0 Fees + 12% APR

USD1 Genesis: 0 Fees + 12% APRUSD1 Genesis: 0 Fees + 12% APR

New users: stake for up to 600% APR. Limited time!